MedTrace Logo

Immunogenicity and Safety Study of Serum-Free Avonex

NCT00912860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2009-06-10

No results posted yet for this study

Summary

To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.

Conditions

Interventions

DRUG

Interferon beta-1a

serum free Avonex given IM once a week

Sponsors & Collaborators

Principal Investigators

  • Biogen-Idec Investigator · Biogen

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2004-12-31
Completion
2005-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00912860 on ClinicalTrials.gov